TY - JOUR
T1 - Ulcerative colitis
AU - OrdaÌs, Ingrid
AU - Eckmann, Lars
AU - Talamini, Mark
AU - Baumgart, Daniel C.
AU - Sandborn, William J.
N1 - Funding Information:
DCB has received research support from Abbott, Astellas, Biocodex, Facet Biotech, and Shire; fees for consultancy from Abbott, AstraZeneca, Bayer Schering Pharma, Cellerix, TiGenix, Genentech, medac autoimmun, MSD, Otsuka, Facet Biotech, UCB; and lecture fees from Abbott, AstraZeneca, Dr Falk Pharma, Ferring, MSD, Otsuka, Shire, and UCB. All DCB's activities and contracts are in conformity with the FSA-Kodex Fachkreise (voluntary self-monitoring code for expert consultants to the pharmaceutical industry), have been checked by the legal Department of Charité Universitätsmedizin Berlin, and have been approved by the directorate of the Faculty of Medicine of Charité Universitätsmedizin Berlin. WJS has received research support from Abbott Laboratories, Bristol Meyers Squibb, Genentech, Glaxo Smith Kline, Janssen, Takeda, Novartis, Pfizer, Procter and Gamble Pharmaceuticals, Shire Pharmaceuticals, and UCB Pharma; fees for consultancy from Abbott Laboratories, ActoGeniX NV, AGI Therapeutics, Alba Therapeutics Corporation, Albireo, Alfa Wasserman, Amgen, AM-Pharma BV, Anaphore, Astellas Pharma, Athersys, Atlantic Healthcare Limited, Aptalis, BioBalance Corporation, Boehringer-Ingelheim Inc, Bristol Meyers Squibb, Celegene, Celek Pharmaceuticals, Cellerix SL, Cerimon Pharmaceuticals, ChemoCentryx, CoMentis, Cosmo Technologies, Coronado Biosciences, Cytokine Pharmasciences, Eagle Pharmaceuticals, Eisai Medical Research, Elan Pharmaceuticals, EnGene, Eli Lilly Enteromedics, Exagen Diagnostics, Ferring Pharmaceuticals, Flexion Therapeutics, Funxional Therapeutics Limited, Genzyme Corporation, Roche, Gilead Sciences, Given Imaging, Glaxo Smith Kline, Human Genome Sciences, Ironwood Pharmaceuticals, Janssen, KaloBios Pharmaceuticals, Lexicon Pharmaceuticals, Lycera Corporation, Meda Pharmaceuticals, Merck Research Laboratories, MerckSerono, Millennium Pharmaceuticals, Nisshin Kyorin Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, Optimer Pharmaceuticals, Orexigen Therapeutics, PDL Biopharma, Pfizer, Procter and Gamble, Prometheus Laboratories, ProtAb Limited, Purgenesis Technologies, Relypsa, Salient Pharmaceuticals, Salix Pharmaceuticals, Santarus, Schering Plough Corporation, Shire Pharmaceuticals, Sigmoid Pharma Limited, Sirtris Pharmaceuticals, , SLA Pharma (UK) Limited, Targacept, Teva Pharmaceuticals, Therakos, Tillotts Pharma AG, TxCell SA, UCB Pharma, Viamet Pharmaceuticals, Vascular Biogenics Limited, Warner Chilcott UK Limited, and Pfizer; and lecture fees from Abbott Laboratories, Bristol Meyers Squibb, Janssen. All other authors declare that they have no conflicts of interest.
PY - 2012/11
Y1 - 2012/11
N2 - Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided colitis might have a caecal patch of inflammation. Bloody diarrhoea is the characteristic symptom of the disease. The clinical course is unpredictable, marked by alternating periods of exacerbation and remission. In this Seminar we discuss the epidemiology, pathophysiology, diagnostic approach, natural history, medical and surgical management, and main disease-related complications of ulcerative colitis, and briefly outline novel treatment options. Enhanced understanding of how the interaction between environmental factors, genetics, and the immune system results in mucosal inflammation has increased knowledge of disease pathophysiology. We provide practical therapeutic algorithms that are easily applicable in daily clinical practice, emphasising present controversies in treatment management and novel therapies. Â
AB - Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided colitis might have a caecal patch of inflammation. Bloody diarrhoea is the characteristic symptom of the disease. The clinical course is unpredictable, marked by alternating periods of exacerbation and remission. In this Seminar we discuss the epidemiology, pathophysiology, diagnostic approach, natural history, medical and surgical management, and main disease-related complications of ulcerative colitis, and briefly outline novel treatment options. Enhanced understanding of how the interaction between environmental factors, genetics, and the immune system results in mucosal inflammation has increased knowledge of disease pathophysiology. We provide practical therapeutic algorithms that are easily applicable in daily clinical practice, emphasising present controversies in treatment management and novel therapies. Â
UR - http://www.scopus.com/inward/record.url?scp=84868207481&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84868207481&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(12)60150-0
DO - 10.1016/S0140-6736(12)60150-0
M3 - Article
C2 - 22914296
AN - SCOPUS:84868207481
VL - 380
SP - 1606
EP - 1619
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9853
ER -